Innovative Small Molecules for Safe Weight Loss and Lean Muscle Mass Preservation

Description

This technology is a class of small molecules designed to treat obesity and obesity-related metabolic dysfunctions, including type 2 diabetes. These molecules show significant weight loss in preclinical mouse models without suppressing appetite or reducing physical activity. Importantly, they preserve lean muscle mass while reducing fat, a critical factor in maintaining long-term metabolic health. Studies have also shown favorable toxicological profiles and enhanced beta-cell function in obese mice. Additionally, they can be conveniently formulated as tablets or capsules, making them suitable for long-term patient use.

According to WHO, 1 in 8 people in the world were living with obesity in 2022. In 2024, 35 million children under the age of 5 were overweight. Obesity can lead to increased risk of type 2 diabetes and heart disease, affecting bone health and reproduction. With the global prevalence of these conditions on the rise, there remains an urgent need for an effective, well-tolerated therapeutic option.

Benefits

• Effective Weight Loss Without Appetite Suppression: Reduces body weight through mechanisms that do not impact food consumption or activity levels.
• Preservation of Lean Muscle Mass: Promotes fat loss while maintaining muscle mass, supporting better metabolic and physical outcomes.
• Safe and Multifunctional: Demonstrates good tolerability and improves beta-cell function, acting through multiple anti-obesity pathways.
• Oral Delivery: Convenient oral administration that replaces the need for injections and fits into everyday routines.

Applications

• Obesity
• Type 2 Diabetes
• Weight management

Patent Status

• Provisional filed

Publications